Loading company…
Fujisawa-based biotech developing drugs that target RNA for genetic rare diseases, founded in 2018.
Founded in 2018 in Fujisawa-shi, Japan, Reborna Biosciences, Inc. develops therapies for genetic rare diseases using drug discovery technology for low molecular weight drugs that bind RNA. Its pipeline includes orally administered drugs intended to ease the burden of long-term treatment. In May 2023 it raised JPY 670 million in Series D funding led by Nissay Capital, with participation from Angel Bridge, Shionogi Pharmaceutical and Toho Holdings, at a valuation of JPY 1,670.588 million. Its products are aimed at markets in North America, Europe and parts of Asia.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in